Hudson Caetano Polonini

Hudson Caetano Polonini

Universityof Juiz de Fora, Brazil

Title: Improving bioavailabilty of Resveratrol: Transdermal, transmucosal and nanotechnology strategies


Hudson Polonini, pharmacist, has completed his PhD at 2014 from Federal University of Juiz de Fora and currently performs postdoctoral studies from Federal University of Santa Catarina. He studies: analysis and control of medicines and related products, pharmaceutical and cosmeceutical technology, biopharmacy, natural products and ecotoxicology. He has published 30 papers in reputed journals and he has two patents, and he also has some awards in innovation competitions.


Resveratrol (3,5,4-trihydroxystilbene) is a prominent substance in currently pharmaceutical research. It is a naturally occurring non-flavanoid phenolic compound produced by some spermatophytes, notably grapes (reason why it is found in high concentrations in many red grape skins and their wines). The trans-resveratrol isomer is more biologically active: it has been reported to possess antioxidant, neuroprotective, antiphotoaging and antiviral activities, and it also seems to play a role in the prevention and reduction of pathological processes such as inflammation, cancer and heart diseases. However, trans-resveratrol has poor oral bioavailability, which creates a dilemma between its great in vitro efficacy and its low in vivo effect, mainly because it is extensively metabolized in the body. Our group has been dealing with this question. Two previous published studies on its permeations through excised human skin showed that this can be a good alternative to avoid the oral route. They used different methods and obtained very similar results of permeation percentage from emulsions (62.6 % using retention mapping and 64.9% using tape stripping). Another strategies that are currently under evaluation in our laboratory is the transmucosal route, either by oral or vaginal mucosal. Our preliminary results show that these seem to be also efficient routes, as they can act both for systemic drug delivery as for local clinical conditions. Finally, the inclusion of trans-resveratrol in solid lipid nanoparticles (SLN) is will offer additional advantages of stability and delivery of the substance to the body, as shown by the results obtained until now. In addition, toxicology studies are been run in parallel. These data altogether show that these alternative strategies can be safe and of clinical relevance for a more efficient delivery of resveratrol to humans.Thus, transdermal or transmucosal delivery of resveratrol is paramount for the effective insertion of the substance into pharmaceuticals for clinical practice.

Speaker Presentations

Speaker PPTs

Download PPT